Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;39(5):1589-1612.
doi: 10.1007/s12640-021-00381-7. Epub 2021 Jun 25.

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review

Affiliations
Review

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review

Sedigheh Eskandari et al. Neurotox Res. 2021 Oct.

Abstract

Neurodegenerative diseases such as stroke and Alzheimer's disease (AD) are two inter-related disorders that affect the neurons in the brain and central nervous system. Alzheimer's is a disease by undefined origin and causes. Stroke and its most common type, ischemic stroke (IS), occurs due to the blockade of cerebral blood vessels. As an important feature, both of disorders are associated with irreversible damages to the brain and nervous system. In this regard, finding common signaling pathways and the same molecular origin between these two diseases may be a promising way for their solution. On the basis of literature appraisal, the most common signaling cascades implicated in the pathogenesis of AD and stroke including notch, autophagy, inflammatory, and insulin signaling pathways were reviewed. Furthermore, current therapeutic strategies including natural and synthetic pharmaceuticals aiming modulation of respective signaling factors were scrutinized to ameliorate neural deficits in AD and stroke. Taken together, digging deeper in the common connections and signal targeting can be greatly helpful in understanding and unified treating of these disorders.

Keywords: Alzheimer’s disease; Neurodegenerative disorders; Signaling pathways; Stroke; Therapeutic strategy.

PubMed Disclaimer

References

    1. 2018 Alzheimer's disease facts and figures (2018) Alzheimer's & Dementia 14:367–429. https://doi.org/10.1016/j.jalz.2018.02.001
    1. Abd-Elrahman KS, Hamilton A, Vasefi M, Ferguson SSG (2018) Autophagy is increased following either pharmacological or genetic silencing of mGluR5 disease signaling in Alzheimer's mouse models. Mol Brain 11:19. https://doi.org/10.1186/s13041-018-0364-9
    1. Abdul-Rahman O, Sasvari-Szekely M, Ver A, Rosta K, Szasz BK, Kereszturi E, Keszler G (2012) Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics 13:81–81. https://doi.org/10.1186/1471-2164-13-81
    1. Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, Iadecola C (2010) Key role of CD36 in toll-like receptor 2 signaling in cerebral ischemia. Stroke 41:898–904. https://doi.org/10.1161/STROKEAHA.109.572552
    1. Albright CF et al (2013) Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther 344:686–695 - PubMed - DOI - PMC

MeSH terms

Substances

LinkOut - more resources